AXGT - New commercial chief at Axovant Gene Therapies

Axovant Gene Therapies (AXGT) appoints Kristiina Vuori, M.D., Ph.D., to its Board of Directors and the promotes Parag. V. Meswani, Pharm.D., from SVP, Commercial Strategy & Operations to Chief Commercial Officer ((CCO)), effective October 6, 2020. Dr. Vuori is a Professor at the Sanford Burnham Prebys Medical Discovery Institute, where she also serves as President and member of the Board of Directors. Dr. Meswani, has served in various commercial and medical affairs leadership roles at Novartis, Pharmacia, Biogen, and most recently, Spark Therapeutics.At Spark, he served as head of U.S. marketing and diagnostics, leading the development and execution of the brand strategy for LUXTURNA, the first approved gene therapy in the U.S.Shares up 3% premarket.

For further details see:

New commercial chief at Axovant Gene Therapies